Top Tech Companies (2,065)
Don't see your company?
Create a company profile
We use nature’s own technology to make fruits and vegetables last longer in order to drastically reduce food waste—from farmer to grocer to kitchen tables around the world. JOIN OUR TEAM. Check out http://www.apeel.com/jobs for career opportunities. You’ll join a group of committed, passionate individuals who are excited about the opportunity to build and implement new technologies with a global reach. INTERNSHIP OPPORTUNITIES. We hire undergraduate and graduate-level students with backgrounds in Chemistry, Biology, Engineering, Materials, Computer Science, Math, Statistics, and related fields. Apeel's investors include Andreessen Horowitz, DBL Partners, Upfront Ventures, S2G Ventures, Powerplant Ventures, The Bill & Melinda Gates Foundation, and The Rockefeller Foundation. Visit us at apeel.com to learn more.
We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases.
Atavistik Bio is a new, privately-held biopharmaceutical company focused on the discovery and development of novel therapies for metabolic diseases and cancer. Our high-throughput platform for the unbiased identification of metabolite-protein interactions will enable the discovery of first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. Our unique approach marries this validated platform with structure-aided drug design capabilities and cutting-edge insights into the regulation of metabolic systems to apply to genetically validated targets.
Cullinan Oncology is dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners. Anchored in a deep understanding of immuno-oncology and translational cancer medicine, we leverage our scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across cancer indications
At Accuray, we make a direct and powerful impact on the lives of cancer patients every day — helping them live longer, better lives. But our commitment to innovation offers a truly unique opportunity: the chance to change the fight against cancer — helping to develop, introduce and support new treatment delivery systems and software that will give new hope and new health to cancer patients and cancer survivors around the world. Accuray develops, manufactures and sells radiotherapy systems for alternative cancer treatments. Our radiation therapy for cancer makes treatment shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives.
Abpro Corporation is a clinical-stage biotechnology company located in Woburn, Massachusetts. The Company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro’s DiversImmune™ platform has been used successfully against 300 traditionally difficult targets. The Company has a pipeline of therapies to treat cancer, eye, autoimmune, infectious diseases and other areas. For more information, please visit https://abpro.com/
Outpace Bio is a venture-backed biotechnology company building a platform to create next-generation smart cell therapies. Our world-class scientific team is developing cell therapies that intervene in complex biology in ways that small molecules and biologics cannot. Our rich platform combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. We create mechanism-driven solutions tailor-made to dramatically improve efficacy and safety. Our partnership business model will accelerate the clinical validation of our platform and the development of truly curative therapies. We value teamwork, creativity, integrity, rigor, and passion for science. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.
Our mission is to cure disease by writing the code of life
Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. We help our customers #SimplifyProgress from drug discovery to manufacturing so that more people can have access to better medicine. With this, we are #PartOfTheSolution in the fight against diseases worldwide. With innovative laboratory instruments and consumables, the our Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. Based in Göttingen, Germany, Sartorius also has a strong global reach with around 60 production and sales sites worldwide. We regularly expand our portfolio through the acquisition of complementary technologies. In 2023, Sartorius generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees from around 110 nations are working for customers around the globe. Join our team, partner or collaborate with us.
Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment. Through a cfDNA technology platform approach, we've pioneered noninvasive testing in unlimited applications—each with their own potential to revolutionize care for patients. #TeamNatera includes clinicians, scientists, biostatisticians, researchers, and laboratory professionals from around the world. Our diverse teams blend a passion for patients with deep clinical, scientific, and technological roots. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy.
We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass.
Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a foundationally different approach to thrombus reduction, the company manufactures intravenous catheters from a hydrophilic material which retains significant amounts of water. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade the foreign body response and complications that come with it. Our cleared products are HydroPICC®and HydroMID®. For more information, please visit www.accessvascularinc.com.
Seed Health is a microbial sciences company pioneering applications of microbes for human and planetary health. In collaboration with leading academic researchers, we advance breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics, consumer health innovations and environmental solutions. All consumer innovations in probiotics are commercialized under Seed®.
4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Executive Relentlessly
Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. We bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them most.
Orthofix Medical Inc. began in a small farmhouse in Verona Italy in 1980 when orthopedic researcher Giovanni De Bastiani recognized the bone’s natural repair capability, a concept he called “dynamization.” With that in mind, he created the first external fixation device. Today, Orthofix has grown to more than 1,200 employees with locations in the U.S., Italy, Germany, France, the U.K., Brazil, and Australia. Our products help patients in more than 70 countries around the world. The Company’s mission is to deliver innovative, quality-driven solutions as we partner with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, the company has two strategic business units: Spine and Orthopedics. Orthofix products are widely distributed via the company's sales representatives and distributors. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as MTF Biologics, the Orthopedic Research and Education Foundation, and the Texas Scottish Rite Hospital for Children. Orthofix makes a difference in the lives of others by providing our surgeon customers with innovative medical devices to meet the needs of their patients. Every day we are optimizing our operations, improving efficiencies, and examining our systems to provide the best support possible to our representatives, surgeons and patients.
Landmark Bio is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing technologies for the new generation of medicines to come. Founding partners include Harvard University, Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies (FDB), and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Mass General Brigham, and the Dana-Farber Cancer Institute. For more information please contact [email protected]
Madison Core Laboratories (MCL) is a state-of-the-art full service locally based independent clinical laboratory. Our clients include physician offices, long-term care facilities, assisted living facilities, homebound patients, addiction clinics, and industrial/corporate testing needs. MCL is one of the leading independent laboratories in Alabama. We provide extensive laboratory services using state-of-the art testing equipment to provide our clients with the latest innovations in the laboratory spectrum. We provide mobile services, rapid courier pickups, timely, and accurate results. MCL placed 123rd on the 2022 Inc. Magazine’s list of fastest-growing companies in the Southeast. Our main facility is in Huntsville, Alabama which has been named the Number 1 Best Place to Live by U.S. News & World Report for 2022-2023.
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
